▎ 摘　　要

NOVELTY - Polypeptide nanomicelle are formed by self-assembly of PEGylated phospholipids and cancer-targeting polypeptides, where the cancer-targeting polypeptide is a polypeptide capable of targeted binding to cancer cells or cancer tissues overexpressing EZH2. USE - The polypeptide nanomicelle is useful in preparation of drugs for treating cancer by inhibiting proliferation of cancer cells or cancer tissues that express or overexpress EZH2. The cancer is chosen from one or more of small cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer or gastric cancer, preferably small cell lung cancer or non-small cell lung cancer (claimed). ADVANTAGE - The nanomicelles have better stability in serum-containing solutions as compared with free peptides, exhibit stronger properties of inhibiting tumor cell proliferation, and provides feasible methods and technologies for inhibiting tumor cell proliferation and treating cancer. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) method for preparing the polypeptide nanomicelles involves (a) preparing PEGylated phospholipid molecule solution and polypeptide molecule solution separately, and (b) mixing PEGylated phospholipid molecule solution and polypeptide molecule solution, incubating the mixture, and allowing it to stand to obtain polypeptide nanomicelle solution; and (2) use of the polypeptide nanomicelles in preparation of drugs for treating cancer, where the drug for treating cancer is a drug for inhibiting cancer proliferation, or a cancer drug that inhibits cancer cells or cancer tissues that express or overexpress EZH2, and the cancer is chosen from one or more of small cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer or gastric cancer, preferably small cell lung cancer or non-small cell lung cancer.